(Q37245017)

19 August 2017

Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. (English)

1 reference

19 August 2017

0 references

1 reference

1 reference

1 reference

1 reference

5

Cécile Goujard

1 reference

19 August 2017

3

Anne-Marie Taburet

1 reference

19 August 2017

6

France Mentré

1 reference

19 August 2017

Xavière Panhard

1

1 reference

19 August 2017

Mayeule Legrand

series ordinal

2

1 reference

19 August 2017

Bertrand Diquet

series ordinal

4

1 reference

19 August 2017

Cophar 1 - ANRS 102 Study Group

series ordinal

7

1 reference

19 August 2017

language of work or name

1 reference

11 August 2007

1 reference

European Journal of Clinical Pharmacology

19 August 2017

1 reference

19 August 2017

63

1 reference

19 August 2017

11

1 reference

19 August 2017

1019-1029

1 reference

https://scigraph.springernature.com/pub.10.1007/s00228-007-0337-x

19 August 2017

0 references

cites work

Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2703659

Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2703659

Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2703659

Ways to fit a PK model with some data below the quantification limit

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2703659

Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2703659

Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2703659

Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2703659

Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2703659

Zalcitabine population pharmacokinetics: application of radioimmunoassay.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2703659

Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2703659

Nonlinear mixed effects models for repeated measures data

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2703659

Pharmacokinetic Optimisation of Antiretroviral Therapy in Patients with HIV Infection

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2703659

Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2703659

Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2703659

Population pharmacokinetics of zidovudine. The Veterans Administration Cooperative Studies Group

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2703659

Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. A phase I trial

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2703659

Population pharmacokinetics of didanosine in patients with human immunodeficiency virus infection

26 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00228-007-0337-X

High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2703659

Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2703659

Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2703659

Determination of twelve antiretroviral agents in human plasma sample using reversed-phase high-performance liquid chromatography.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2703659

Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2703659

Mixed-Effects Models in Sand S-PLUS

3 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00228-007-0337-X

Concentration-controlled zidovudine therapy

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17694300

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Relationship between exposure to zidovudine and decrease of P24 antigenemia in HIV-infected patients in monotherapy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17694300

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00228-007-0337-X

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

17694300

1 reference